Meet CONNECT's newest partner

We are delighted to welcome our newest partner, Daiichi Sankyo.

"We joined CONNECT to collaborate with the key actors who can accelerate access to innovative therapies," said Martin Ahlgren, Medical Director Nordics.

Through their CONNECT partnership, Daiichi Sankyo aims to deepen engagement with clinical investigators, create new opportunities for clinical studies, and help strengthen the Nordic precision-oncology infrastructure. This alignment is crucial for Daiichi Sankyo, as their antibody–drug conjugate (ADC) programmes rely on understanding tumour biology in detail to target the right treatment to the right patient.

 "The platform CONNECT enables earlier dialogue, stronger evidence generation, and better alignment across clinical, scientific, and industry partners—exactly the kind of ecosystem collaboration that improves cancer care," said Ahlgren.

About Daiichi Sankyo

Daiichi Sankyo is a global biopharmaceutical company with over 120 years of experience and a focus on innovative antibody-drug conjugates (ADCs). Based in Tokyo with a European Headquarters in Munich and a Nordic office in Copenhagen since 2019, their 19,000 employees worldwide are dedicated to developing new medicines for patients.